{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:20:17Z","timestamp":1792693217373,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004956.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000}}],"reference-count":80,"publisher":"Wiley","issue":"12","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004956.pub3","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T09:59:57Z","timestamp":1512122397000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Bisphosphonates for Paget's disease of bone in adults"],"prefix":"10.1002","volume":"2017","author":[{"given":"Luis","family":"Corral-Gudino","sequence":"first","affiliation":[{"name":"Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo, SACYL, IBSAL, RETICEF; Internal Medicine Department; c\/Medicos Sin fronteras, 7 Ponferrada Leon Spain 24411"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian JH","family":"Tan","sequence":"additional","affiliation":[{"name":"Western General Hospital; Rheumatic Diseases Unit; Edinburgh UK EH4 2XU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"del Pino-Montes","sequence":"additional","affiliation":[{"name":"University of Salamanca, University Hospital of Salamanca, IBSAL, RETICEF; Department of Medicine, Service of Rheumatology; Paseo San Vicente 54 Salamanca Salamanca Spain 37007"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart H","family":"Ralston","sequence":"additional","affiliation":[{"name":"University of Edinburgh; Centre for Genomic and Experimental Medicine; Western General Hospital Edinburgh UK EH4 2XU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,1]]},"reference":[{"issue":"26","key":"10.1002\/14651858.CD004956.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJM197312272892601","article-title":"Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)","volume":"289","author":"Altman","year":"1973","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004956.pub3-BIB0002|cit2","first-page":"SU0164","article-title":"Double blind, double dummy, randomized controlled trial of oral bisphosphonates (OB) in the treatment of active paget's bone disease (PBD)","volume":"26","author":"Barreira","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0003|cit3","first-page":"179","article-title":"Double blind, double dummy, randomized controlled trial of oral bisphosphonates (OB) in the treatment of active Paget's bone disease (PBD)","volume":"20","author":"Barreira","year":"2009","journal-title":"Osteoporosis International"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD004956.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S8756-3282(99)00071-X","article-title":"Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study","volume":"24","author":"Buckler","year":"1999","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004956.pub3-BIB0005|cit5","first-page":"S373","article-title":"A double blind placebo-controlled trial using intravenous zoledronate (CGP 42446) in patients with Paget's disease of bone","volume":"11","author":"Schaffer","year":"1996","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/jcem-44-1-96","article-title":"Diphosphonate therapy of Paget's disease of bone","volume":"44","author":"Canfield","year":"1977","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"862","key":"10.1002\/14651858.CD004956.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/pgmj.73.862.496","article-title":"A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone","volume":"73","author":"Fraser","year":"1997","journal-title":"Postgraduate Medical Journal"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1359\/jbmr.090709","article-title":"Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone","volume":"25","author":"Langston","year":"2010","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004956.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/8756-3282(95)00282-1","article-title":"Tiludronate therapy for Paget's disease of bone","volume":"17","author":"McClung","year":"1995","journal-title":"Bone"},{"issue":"10","key":"10.1002\/14651858.CD004956.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","article-title":"Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone","volume":"22","author":"Merlotti","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD004956.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/jbmr.5650070112","article-title":"Effects of five daily 1 h infusions of alendronate in Paget's disease of bone","volume":"7","author":"O'Doherty","year":"1992","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/8756-3282(87)90168-2","article-title":"Biochemical response to combination of disodium etidronate with calcitonin in Paget\u2019s disease","volume":"8","author":"O'Donoghue","year":"1987","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jbmr.5650020103","article-title":"The effect of 1 alpha-hydroxyvitamin D3 on the mineralization defect in disodium etidronate-treated Paget's disease - a double-blind randomized clinical study","volume":"2","author":"Ralston","year":"1987","journal-title":"Journal of Bone and Mineral Research"},{"issue":"8","key":"10.1002\/14651858.CD004956.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/art.1780350819","article-title":"Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study","volume":"35","author":"Reginster","year":"1992","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0002-9343(96)00227-6","article-title":"Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial","volume":"101","author":"Reid","year":"1996","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bone.2004.03.023","article-title":"Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone","volume":"35","author":"Reid","year":"2004","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00223-016-0214-7","article-title":"Long-term effects of intravenous ibandronate in Paget\u2019s disease of bone","volume":"100","author":"Reid","year":"2017","journal-title":"Calcified Tissue International"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","article-title":"Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate","volume":"22","author":"Hosking","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD004956.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years","volume":"26","author":"Reid","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD004956.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004956.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/art.1780380620","article-title":"Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone","volume":"38","author":"Roux","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0023|cit23","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD004956.pub3-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1002\/jbmr.3066","article-title":"Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: The PRISM-EZ Study","volume":"32","author":"Tan","year":"2017","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2003.12.011","article-title":"A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone","volume":"34","author":"Walsh","year":"2004","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/8756-3282(94)90818-4","article-title":"Effects of two oral doses of alendronate in the treatment of Paget's disease of bone","volume":"15","author":"Adami","year":"1994","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0027|cit27","first-page":"55","article-title":"Short-term intravenous therapy with neridronate in Paget's disease","volume":"20","author":"Adami","year":"2002","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD004956.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0002-9343(85)90055-5","article-title":"Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone","volume":"79","author":"Altman","year":"1985","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02409437","article-title":"Effects of two diphosphonates (EHDP and Cl2MDP) on serum uric acid in pagetic patients","volume":"33","author":"Arlot","year":"1981","journal-title":"Calcified Tissue International"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jbmr.5650020403","article-title":"Aminohexane diphosphonate in the treatment of Paget's disease of bone","volume":"2","author":"Atkins","year":"1987","journal-title":"Journal of Bone and Mineral Research"},{"issue":"9","key":"10.1002\/14651858.CD004956.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.57.9.572","article-title":"Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone","volume":"57","author":"Buckler","year":"1998","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/jbmr.3029","article-title":"Durability of response to zoledronate treatment and competing mortality in Paget\u2019s disease of bone","volume":"32","author":"Cundy","year":"2016","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-54-4-837","article-title":"Long term effects of dichloromethylene diphosphonate in Paget's disease of bone","volume":"54","author":"Delmas","year":"1982","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S8756-3282(96)00368-7","article-title":"Biological and radiological responses to oral etidronate and tiludronate in Paget's disease of bone","volume":"20","author":"Devogelaer","year":"1997","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00223-013-9812-9","article-title":"Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid","volume":"94","author":"Devogelaer","year":"2014","journal-title":"Calcified Tissue International"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.44.1.34","article-title":"Clinical experience with the use of two diphosphonates in the treatment of Paget's disease","volume":"44","author":"Dewis","year":"1985","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keg477","article-title":"Effect of bisphosphonate treatment in patients with Paget's disease of the skull","volume":"43","author":"Don\u00e1th","year":"2004","journal-title":"Rheumatology (Oxford, England)"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/8756-3282(94)90287-9","article-title":"Effects of two different bisphosphonates on Paget's disease of bone: ICTP assessed","volume":"15","author":"Filipponi","year":"1994","journal-title":"Bone"},{"issue":"12","key":"10.1002\/14651858.CD004956.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1136\/ard.50.12.930","article-title":"Clinical experience with pamidronate in the treatment of Paget's disease of bone","volume":"50","author":"Gallacher","year":"1991","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004956.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1529-0131(199802)41:2<354::AID-ART20>3.0.CO;2-5","article-title":"Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease","volume":"41","author":"Garnero","year":"1998","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD004956.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S8756-3282(01)00431-8","article-title":"The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone","volume":"28","author":"Garnero","year":"2001","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD004956.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1148\/117.2.365","article-title":"Radionuclide uptake studies of bone: a quantitative method of evaluating the response of patients with Paget's disease to diphosphonate therapy","volume":"117","author":"Goldman","year":"1975","journal-title":"Radiology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004956.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S8756-3282(99)00072-1","article-title":"Ibandronate treatment in Paget's disease of bone","volume":"24","author":"Grauer","year":"1999","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S8756-3282(96)00224-4","article-title":"Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study","volume":"19","author":"Gutteridge","year":"1996","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00198-008-0639-6","article-title":"Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease","volume":"20","author":"Hooper","year":"2009","journal-title":"Osteoporosis International"},{"issue":"Suppl","key":"10.1002\/14651858.CD004956.pub3-BIB0046|cit46","first-page":"321","article-title":"Combined diphosphonate and calcitonin therapy for Paget's disease of bone","volume":"21","author":"Hosking","year":"1976","journal-title":"Calcified Tissue Research"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1001\/jama.1974.03240040032027","article-title":"Treatment of Paget disease of bone (osteitis deformans). Results of a one-year study with sodium etidronate","volume":"230","author":"Khairi","year":"1974","journal-title":"JAMA"},{"issue":"6","key":"10.1002\/14651858.CD004956.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-87-6-656","article-title":"Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results","volume":"87","author":"Khairi","year":"1997","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(96)00364-X","article-title":"Alendronate in the treatment of Paget's disease of bone","volume":"20","author":"Khan","year":"1997","journal-title":"Bone"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD004956.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S8756-3282(99)00063-0","article-title":"Treatment of Paget's disease of bone with alendronate","volume":"24","author":"Lombardi","year":"1999","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0051|cit51","first-page":"36","article-title":"Pamidronate infusions for the treatment of Paget's disease of bone","volume":"63","author":"Mazieres","year":"1996","journal-title":"Review du Rhumatisme (English Edition)"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/jbmr.237","article-title":"Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone","volume":"26","author":"Merlotti","year":"2011","journal-title":"Journal of Bone and Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD004956.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/jbmr.5650100714","article-title":"The effects of intravenous alendronate in Paget's disease of bone","volume":"10","author":"O'Doherty","year":"1995","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02229863","article-title":"Paget's disease of bone: five regimens of pamidronate treatment","volume":"13","author":"Pepersack","year":"1994","journal-title":"Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD004956.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/8756-3282(88)90115-9","article-title":"Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone","volume":"9","author":"Reginster","year":"1988","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.52.1.54","article-title":"Paget's disease of bone treated with a five day course of oral tiludronate","volume":"52","author":"Reginster","year":"1993","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"7863","key":"10.1002\/14651858.CD004956.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(74)90347-X","article-title":"Diphosphonates in Paget's disease","volume":"1","author":"Russell","year":"1974","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD004956.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/art.1780231016","article-title":"Long-term therapy of Paget's disease of bone with EHDP","volume":"23","author":"Siris","year":"1980","journal-title":"Arthritis and Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD004956.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/jbmr.5650051207","article-title":"Treatment of Paget's disease with intermittent low-dose infusions of disodium pamidronate (APD)","volume":"5","author":"Stone","year":"1990","journal-title":"Journal of Bone and Mineral Research"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0060|cit60","first-page":"103","article-title":"Preliminary study of multiple increasing oral doses of dimethyl-APD on bone metabolism dynamics and safety profile","volume":"20","author":"Vega","year":"1994","journal-title":"Drugs under Experimental and Clinical Research"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0061|cit61","unstructured":"ISRCTN11616770 Zoledronate in the Prevention of Paget's: the ZiPP study isrctn.com\/show\/ISRCTN11616770"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0062|cit62","unstructured":"NCT02106455 Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance \u2212 clinicaltrials.gov\/show\/NCT02106455"},{"issue":"6","key":"10.1002\/14651858.CD004956.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa1105243","article-title":"Prevention of HIV-1 infection with early retroviral therapy","volume":"365","author":"Cohen","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004956.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bone.2013.04.024","article-title":"Epidemiology of Paget's disease of bone: a systematic review and meta-analysis of secular changes","volume":"55","author":"Corral-Gudino","year":"2013","journal-title":"Bone"},{"issue":"8","key":"10.1002\/14651858.CD004956.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00198-008-0629-8","article-title":"Management of patients with Paget's disease: a consensus document of the Belgian Bone Club","volume":"19","author":"Devogelaer","year":"2008","journal-title":"Osteoporosis International"},{"issue":"9","key":"10.1002\/14651858.CD004956.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1002\/1529-0131(200109)44:9<2201::AID-ART374>3.0.CO;2-E","article-title":"The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith","year":"2001","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0067|cit67","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"7650","key":"10.1002\/14651858.CD004956.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0069|cit69","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"7","key":"10.1002\/14651858.CD004956.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMcp1204713","article-title":"Paget's disease of bone","volume":"368","author":"Ralston","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0071|cit71","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD004956.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0165-4608(03)00105-5","article-title":"Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors","volume":"145","author":"Sandberg","year":"2003","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1002\/14651858.CD004956.pub3-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Schaffer V Buckler H Ryaa W Richardson P Double blind placebo-controlled trial using intraveonous zoledronate (CGP.42446) in patients with Paget\u00b4s diasese of bone. ASBMR 18th Annual Meeting book of abstract August 1996 S373","DOI":"10.1007\/BF02500569"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S8756-3282(02)00817-7","article-title":"Guidelines on the management of Paget's disease of bone","volume":"31","author":"Selby","year":"2002","journal-title":"Bone"},{"issue":"12","key":"10.1002\/14651858.CD004956.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1210\/jc.2014-2910","article-title":"Paget's disease of bone: an Endocrine Society Clinical Practice Guideline","volume":"99","author":"Singer","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9343(97)89432-6","article-title":"A potent new bisphosphonate for Paget's disease of bone","volume":"101","author":"Siris","year":"1996","journal-title":"American Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004956.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00774-006-0696-x","article-title":"Guidelines for diagnosis and management of Paget's disease of bone in Japan","volume":"24","author":"Takata","year":"2006","journal-title":"Journal of Bone and Mineral Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD004956.pub3-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00223-014-9904-1","article-title":"Clinical presentation of Paget\u2019s disease: evaluation of a contemporary cohort and systematic review","volume":"95","author":"Tan","year":"2014","journal-title":"Calcified Tissue International"},{"issue":"3","key":"10.1002\/14651858.CD004956.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.2002.17.3.465","article-title":"Incidence and natural history of Paget's disease of bone in England and Wales","volume":"17","author":"Staa","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD004956.pub3-BIB0080|cit80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004956","article-title":"Aminobisphosphonates versus other active treatment for Paget's disease of the bone in adults","author":"Langston","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004956.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T06:48:40Z","timestamp":1704264520000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004956.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":80,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004956.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}